DHG Pharmaceutical JSC
DHG Pharmaceutical Joint Stock Company, together with its subsidiaries, engages in the manufacture and sale of pharmaceutical products in Vietnam. The company offers antibiotic, analgesic and antipyretic, respiratory, nutrition, musculoskeletal, gastrointestinal and hepatobiliary, nervous and ophthalmic, cardiovascular and diabetic, and dermatology and beauty care products. It also manufactures a… Read more
DHG Pharmaceutical JSC (DHG) - Total Liabilities
Latest total liabilities as of December 2025: ₫983.26 Billion VND
Based on the latest financial reports, DHG Pharmaceutical JSC (DHG) has total liabilities worth ₫983.26 Billion VND as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
DHG Pharmaceutical JSC - Total Liabilities Trend (2019–2025)
This chart illustrates how DHG Pharmaceutical JSC's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
DHG Pharmaceutical JSC Competitors by Total Liabilities
The table below lists competitors of DHG Pharmaceutical JSC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Siam Pan Group PCL
BK:SPG
|
Thailand | ฿457.05 Million |
|
Scilex Holding Company
NASDAQ:SCLX
|
USA | $455.60 Million |
|
Ganesh Benzoplast Limited
NSE:GANESHBE
|
India | ₹1.81 Billion |
|
Home Federal Bancorp Louisiana
NASDAQ:HFBL
|
USA | $563.70 Million |
|
Indo Tech Transformers Limited
NSE:INDOTECH
|
India | ₹1.86 Billion |
|
Chi Hua Fitness Co Ltd
TWO:1593
|
Taiwan | NT$688.93 Million |
|
BMT Co. Ltd
KQ:086670
|
Korea | ₩103.66 Billion |
|
Samsung Climat
KO:006660
|
Korea | ₩45.28 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down DHG Pharmaceutical JSC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DHG Pharmaceutical JSC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DHG Pharmaceutical JSC (2019–2025)
The table below shows the annual total liabilities of DHG Pharmaceutical JSC from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₫983.26 Billion | -47.26% |
| 2024-12-31 | ₫1.86 Trillion | +48.26% |
| 2023-12-31 | ₫1.26 Trillion | +43.45% |
| 2022-12-31 | ₫876.65 Billion | +6.32% |
| 2021-12-31 | ₫824.52 Billion | -6.25% |
| 2020-12-31 | ₫879.46 Billion | +14.32% |
| 2019-12-31 | ₫769.27 Billion | -- |